How Common Is Paxlovid Rebound News
No clear association between Paxlovid and COVID-19 rebound, FDA saysABC on MSN.com7 days ago
An FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and...
“COVID Rebound” Is Common – Even in Patients Not Treated With PaxlovidSciTech Daily1 week ago
Preliminary results from a Scripps Research and eMed digital medicine study show an unexpectedly high proportion of COVID-19 rebound cases in untreated people, as well as those treated with Paxlovid.
In a recently published retrospective review of Mayo Clinic patients, Shah found that about 1 percent of Paxlovid users rebounded, which is consistent with the Pfizer clinical trial. But based on...
What is the rebound effect of Paxlovid? There have been reports of a “rebound” of COVID-19 symptoms in some people within 2 to 8 days after completing the five-day course of Paxlovid; in those cases, some have tested positive again but have no symptoms; others have a recurrence of symptoms.
Doctors interviewed by ABC News put the real estimate of Paxlovid rebound at anywhere from 10 percent to as much as 30 percent of cases, even though no one knows for sure. "I'm telling them (patients), it's very common," said Dr. George Diaz, of the Infectious Disease Society of American of Paxlovid rebound.
Some of the people in the comparison group also experienced rebound – though it appeared to be less common for these patients compared to the group that took Paxlovid. About 9% of the 43...
- What is 'Paxlovid rebound' and how common is it?YouTube
- 'Rebound' Covid Infections After Paxlovid Becomes Focus Of InquiryYouTube
- What is COVID Rebound After Paxlovid? A Doctor ExplainsYouTube
- What is a Paxlovid rebound?YouTube
The researchers found that about 1% of patients treated with Paxlovid experienced a rebound of symptoms, an average of about nine days after treatment. The study was retrospective and could not...
After a clinical trial showed that Paxlovid could reduce the risk of hospitalization and death from COVID-19 by 89 percent, the drug was made available under an emergency use authorization from the U.S. Food and Drug Administration in December 2021.
When Paxlovid was first granted emergency use authorization ( EUA ), manufacturer Pfizer reported that cases of COVID-19 rebound happened to between 1% and 2% of people taking Paxlovid. These rates were similar to people who took a placebo (a pill with no medication in it) during clinical trials.